Related Experiment Video

Updated: Jul 6, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Effect of increasing doses of aspirin on platelet aggregation among stroke patients

Robert Gan1, Rosalia A Teleg, Leila Florento

  • 1Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines, Manila, Philippines. rgan@info.com.ph

Cerebrovascular Diseases (Basel, Switzerland)
|October 31, 2002
PubMed

Insights

Low-dose aspirin (80-160 mg) optimally inhibits collagen-induced platelet aggregation in stroke patients. Higher doses up to 1,300 mg show continued, though less pronounced, dose-dependent inhibition of ADP-induced aggregation.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Neurology

Background:

  • Aspirin is recognized for reducing myocardial infarction and stroke risk.
  • The optimal dose for aspirin's antiplatelet effects remains debated.
  • Some evidence suggests low-dose aspirin matches high-dose efficacy in platelet inhibition.

Purpose of the Study:

  • To evaluate the dose-response relationship of aspirin on platelet aggregation.
  • To compare aspirin's effect on collagen- and ADP-induced platelet aggregation.
  • To determine optimal aspirin dosage for stroke patient management.

Main Methods:

  • Sixteen poststroke patients received escalating daily aspirin doses (40-1,300 mg) for 14 days each.
  • Platelet-rich plasma was analyzed for aggregation response to collagen and ADP.
  • Baseline and post-dose aggregation levels were measured throughout the 12-week study.

Main Results:

  • Aspirin demonstrated dose-dependent inhibition of collagen-induced platelet aggregation, optimal at 80-160 mg/day.
  • Inhibition of ADP-induced platelet aggregation was dose-dependent up to 1,300 mg/day.
  • Significant antiplatelet effects were observed starting from 40 mg/day.

Conclusions:

  • Optimal aspirin dosage for inhibiting collagen-induced platelet aggregation in stroke patients is 80-160 mg/day.
  • ADP-induced platelet aggregation inhibition by aspirin is dose-dependent, extending to higher doses (1,300 mg/day).
  • These findings aid in optimizing aspirin therapy for stroke prevention.
Abstract

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...